MARIO-3 (Macrophage Reprogramming in Immuno-Oncology) (NCT03961698) incorporates pre- and on-treatment tissue biopsies to correlate the effects of eganelisib on PD-L1 expression in tumor-infiltrating immune cells. The gene discussed is CD274; the disease is neoplasm.